Molteno管植入术治疗角膜移植术后难治性青光眼

目的:研究Molteno管植入术治疗穿透性角膜移植术后继发青光眼的手术疗效。方法:对9例眼部条件极差,经最大剂量药物治疗不能降低眼压的穿透性角膜移植术后青光眼施行Molteno管植入手术。结果:7例眼压控制在0.8～2.8kPa(1kPa=7.5mmHg)之间,成功率为77.78％(7/9);另两例需继续局部滴用β-受体阻滞剂,1例发生角膜排斤反应经药物治疗痊愈,1例角膜半透明,角膜植片透明率88.89％(8/9),术后视力有改善者4例,视力保持不变者4例,视力下降者1例,其中4例最好矫正视力大于0.05。结论:Molteno管植入术为角膜移植术后保留一定有视力而又不具作滤过性手术条件的难治性青光眼提供合理、有效的治疗方法。眼科学报1999;15:107-110。     

Molteno implantation for secondary glaucomas associated with advanced epithelial ingrowth

Nine patients with advanced epithelial ingrowth underwent Molteno implantation for medically uncontrollable secondary glaucomas. Substantial reductions in intraocular pressures (IOPs) were observed in most patients (preoperative IOPs ranged from 5 to 48 mmHg [mean +/- standard deviation, 33.6 +/- 14.6 mmHg]; postoperative IOPs ranged from 10 to 30 mmHg [mean +/- standard deviation, 16.0 +/- 6.5 mmHg]); follow-up ranged from 9 to 47 months (mean +/- standard deviation, 18.8 +/- 12.1 months). Seven (78%) patients had final postoperative IOPs of less than 22 mmHg, five (56%) retained formed vision (visual acuity of at least 1/200), and six (67%) remained comfortable. Postoperative complications related to Molteno implantation included one case each of: conjunctival wound leak, vitreous-tube block, tube-cornea touch, and iris-tube block (or tube retraction). Complications attributed to epithelial ingrowth included five cases of corneal decompensation with band keratopathy. Molteno implantation is an effective technique for palliative treatment of secondary glaucomas associated with advanced epithelial ingrowth, frequently maintaining modest vision and comfort in eyes in which the intraocular epithelialization is too extensive for surgical removal and/or destruction.     

Long-term results of eyes with penetrating keratoplasty and glaucoma drainage tube implant

PURPOSE: To present long-term results of eyes with penetrating keratoplasty (PK) and glaucoma tube implant. DESIGN: Retrospective, noncomparative, interventional case series. PARTICIPANTS: We retrospectively reviewed medical records of all patients who underwent both PK and glaucoma tube implant (Baerveldt or Ahmed) at the University of Iowa between July of 1988 and December of 1997 (55 eyes). METHODS: Success of the tube implant or PK was evaluated using Kaplan-Meier survival analysis. Association of relevant clinical factors with glaucoma or corneal graft outcome was evaluated using log-rank test or Cox proportional hazard regression analysis. The factors evaluated were glaucoma and cornea diagnoses; prior, simultaneous, and subsequent surgeries; type of tube implant; relative timing of surgeries; and postsurgical complications. MAIN OUTCOME MEASURES: Glaucoma outcome was assessed by postoperative intraocular pressure (IOP), number of medications, and need for further glaucoma surgery. Corneal outcome was assessed by graft rejection, failure, and Snellen visual acuity. Surgical procedures before and during the study period, and their complications were evaluated. RESULTS: The mean preoperative intraocular pressure was 29.8 mmHg with an average of 2.9 medications. At last postoperative follow-up, the mean IOP decreased to 14.3 mmHg with 0.7 medication. The tube implant successfully controlled glaucoma in 45 eyes (82%) at 3 years. More severe postsurgical complications were associated with greater glaucoma failure. Graft rejection occurred in 17 eyes, and 7 of these progressed to failure. Nonimmunologic graft failure occurred in an additional 17 eyes (31%). The remaining 31 eyes (56%) had a clear graft. The corneal grafts remained clear in 70% and 55% of eyes at 2 and 3 years, respectively. Corneal graft failure was associated with glaucoma and cornea diagnoses groups, type of tube implant, and relative timing of the two surgeries. Complications occurred in 23 eyes (42%), and 10 of these were serious. CONCLUSIONS: A drainage tube implant can successfully control glaucoma in a majority (82%) of keratoplasty eyes at 3 years. However, the success of corneal grafts is low (55%) at 3 years. Postsurgical complications are not uncommon and are associated with poor glaucoma outcome. Other clinical factors are associated with poor graft outcome.     

引流管植入联合羊膜移植和Molteno植入物治疗角膜移植术后青光眼的研究

目的：探讨房水引流管植入联合羊膜移植对角膜移植术后难治性青光眼的治疗作用。方法：应用α－糜蛋白酶行兔眼后房注射制备青光眼动物模型,把它们随机分为照组、单纯引流管植入组、引流管植入加羊膜移植组、引流管加羊膜支架植入联合羊膜移植组,观察眼内压、管周组织学改变、引流管周组织渗透性,并且比较各治疗组对难治性青光眼的疗效。临床上４１例（４２眼）穿透性角膜移植术后青光眼进行了房水引流管植入联合羊膜移植１２眼和     

小梁切除术联合硅胶片植入治疗难治性青光眼

目的:观察小梁切除术联合巩膜层间硅胶片填充治疗难治性青光眼的效果及并发症。方法:60眼难治性青光眼（包括新生血管性青光眼12眼,无晶体或人工晶体性青光眼14眼,先天性青光眼4眼,滤过性手术失败的青光眼18眼,外伤性青光眼12眼）作小梁切除术联合硅胶片填充于巩膜层间,术后观察其降眼压效果及并发症。结果:术后随访5～34个月（平均18.3个月）,最后一次随访时的眼压范围是17.30～37.19mmHg[平均（23.36±4.06）。Hg],其中38眼（63.3％）术后眼压降至21 mmHg以下,18眼（30％）眼压在21～30 mmHg之间,仅4眼（6.7％）术后眼压高于30 mmHg,术后随访时间内未发现与硅胶片填充有关的严重并发症及硅胶片排斤反应。结论:小梁切除术联合巩膜层间硅胶片植入是治疗难治性青光眼的有效方法,尤其是在我国广大基层医院可以代替昂贵进曰引流性植入物治疗难治性青光眼,因此,值得推广应用。     

穿透性角膜移植治疗人工晶状体植入术后大泡性角膜病变的临床观察

目的 评价穿透性角膜移植术治疗人工晶状体植入术后大泡性角膜病变临床疗效,探讨术中对原人工晶状体的处理。方法 对12例(12只眼)人工晶状体植入术后大泡性角膜病变施行穿透性角膜移植术或穿透性角膜移植术联合手术,观察术后角膜植片及视力变化。结果 随访6～16个月,平均11．2个月,术后临床症状明显缓解或消失,植片保持透明,视力较术前均有提高,其中矫正视力0．02以上11例(0．2以上4例);术后继发性青光眼1例,内皮型排斥反应1例。结论 穿透性角膜移植术是治疗人工晶状体植入术后大泡性角膜病变的一种理想手术方式,不仅能消除刺激症状且能增进视力。术中如何处理人工晶状体应视眼部具体情况。     

Management of uveitic glaucoma with Ahmed glaucoma valve implantation

OBJECTIVE: To evaluate the safety and efficacy of Ahmed glaucoma valve implantation for the management of glaucoma associated with chronic uveitis. DESIGN: Retrospective, noncomparative case series. PARTICIPANTS: Nineteen patients (21 eyes) with chronic uveitis underwent Ahmed glaucoma valve implantation for uncontrolled glaucoma between 1995 and 1998. INTERVENTION: All patients had their uveitis controlled before surgery via immunomodulatory therapy. Ahmed glaucoma valve implantation was performed. Immunosuppression was continued in the early postoperative period for strict control of inflammation. MAIN OUTCOME MEASURES: Control of intraocular pressure (IOP). A secondary outcome measure was the number of antiglaucoma medications required to achieve the desired IOP. Visual acuity and complications associated with the surgery were monitored. RESULTS: The postoperative follow-up averaged 24.5 months. At the most recent visit, all 21 eyes had IOPs between 5 and 18 mmHg. The average pressure reduction after Ahmed glaucoma valve implantation was 23.7 mmHg. The average number of antiglaucoma medicines required to achieve the desired IOP was reduced from 3.5 before surgery to 0.6 after surgery. No eye lost even a single line of Snellen acuity at the most recent postoperative visit. Two eyes developed hypotony in the course of follow-up. One resolved without specific intervention, and the other eye required two autologous blood injections and tube ligature to correct the hypotony. One eye underwent Ahmed glaucoma valve replacement for abrupt valve failure. Two eyes underwent penetrating keratoplasty for reasons believed to be unrelated to the glaucoma surgery. Kaplan-Meier life-table analysis showed a cumulative probability of success after Ahmed glaucoma valve implantation of 94% at 1 year. CONCLUSIONS: Ahmed glaucoma valve implantation can be an effective and safe method in the management of uveitic glaucoma. The authors hypothesize that control of the patients' uveitis, through preoperative and long-term postoperative immunomodulatory therapy, may have contributed to the success rate reported herein.     

Which is better? One or two? A randomized clinical trial of single-plate versus double-plate Molteno implantation for glaucomas in aphakia and pseudophakia.

PURPOSE: Previous studies have suggested that primary double-plate Molteno implantation may be beneficial. Therefore, the authors performed a randomized clinical trial to evaluate the relative effectiveness and safety of single- versus double-plate Molteno implantation. METHODS: From March 1988 to February 1990, 132 patients who underwent Molteno implantation for medically uncontrollable non-neovascular glaucomas in aphakia or pseudophakia were randomly assigned to receive either single- or double-plate implants. RESULTS: The 1- and 2-year life-table success rates (success [survival] defined as 6 mmHg < or = final intraocular pressure [IOP] < or = 21 mmHg without additional glaucoma surgery or devastating complication) were 55% and 46% with single-plate implantation and 86% and 71% with double-plate implantation, respectively. The final postoperative visual acuities were within one line of the preoperative visual acuities or had improved in 73% and 80% of patients, respectively. Choroidal hemorrhages and/or effusions, corneal decompensation, flat anterior chambers, and phthisis bulbi were more common in the patients who had undergone double-plate Molteno implantation; however, transient elevations of IOP during the first few postoperative months were more common in the patients who had undergone single-plate Molteno implantation. CONCLUSIONS: Double-plate Molteno implantation more frequently affords IOP control than single-plate Molteno implantation; however, double plates are associated with greater risks of choroidal hemorrhages and/or effusions, corneal decompensation, flat anterior chambers, and phthisis bulbi.     

Ahmed valve implantation in glaucoma secondary to chronic uveitis

PURPOSE: To evaluate the efficacy of Ahmed valve (AV) implantation in patients with uveitic glaucoma. METHODS: In total, 18 patients (19 eyes) with glaucoma secondary to chronic uveitis, who underwent AV implantation were retrospectively reviewed. Visual acuity, intraocular pressure (IOP), and glaucoma medications at the most recent examination prior to surgery, were compared with those of last postoperative examination. The surgical success was defined as IOP less than 21 mmHg and greater than 4 mmHg without loss of light perception and visually devastating complications at the last postoperative examination. Decrease in the number of glaucoma medications was also a criterion for surgical success. RESULTS: The mean follow-up period was 26+/-9.7 months. The mean preoperative and postoperative IOPs were 33.3+/-9.7 (range, 20-57) mmHg and 17.3+/-10.8 (range, 6-40) mmHg respectively (P<0.0001). The mean number of antiglaucoma medications was 3.5+/-0.8 (range, 2-5) preoperatively and 1.4+/-1.3 (range, 0-4) postoperatively (P<0.0001). Valve occlusion (five eyes, 26.3%) was the most commonly observed complication. Surgical success was achieved in 13 eyes (68.4%). The cumulative probability of success was 94.4% at 1 year and 60% at 2 years. Five eyes (26.3%) with IOP greater than 21 mmHg and one (5.3%) with corneal decompensation requiring penetrating keratoplasty were considered as failures. CONCLUSIONS: The implantation of AV is an effective surgical procedure for the management of uveitic glaucoma. The inflammatory background might contribute to the occurrence of valve occlusion, which is the most common complication. Prevention of this complication is an essential factor for improving the surgical outcome.     

Fibrin glue for preventing immediate postoperative hypotony following glaucoma drainage implant surgery

PURPOSE: To prevent a leak of aqueous around the tube in the immediate postoperative period after glaucoma drainage implant (GDI) surgery. METHODS: A total of 42 eyes of 34 consecutive patients with refractory glaucoma requiring single-plate Molteno implantation were retrospectively reviewed. Peritubular filtration was checked intraoperatively in all filtered eyes. Fibrin glue was used over the scleral flap intraoperatively in every eye with peritubular leakage. All Molteno tubes were completely closed with an absorbable ligature. RESULTS: Peritubular filtration was detected in 11 eyes of 11 patients. All 11 eyes maintained intraocular pressure (IOP) >or= 16 mmHg in the immediate postoperative phase. The mean IOP on the first postoperative day was 30.5 +/- 10 mmHg. After an average follow-up of 6 months, the mean IOP in these 11 eyes was 19.1 +/- 6 mmHg. No complications or Seidel-positive aqueous leak were observed during the follow-up period. CONCLUSIONS: Results suggest that intraoperative use of fibrin glue is a viable option for reducing peritubular filtration and preventing immediate postoperative hypotony after GDI surgery.     

Incidence and management of glaucoma after intravitreal silicone oil injection for complicated retinal detachments.

BACKGROUND: Intravitreal silicone oil injection used for managing complicated retinal detachments can be associated with elevated intraocular pressure (IOP). This study was undertaken to determine the incidence of glaucoma in patients who underwent silicone oil injection, as well as to evaluate the effectiveness of medical and surgical therapy in patients in whom glaucoma developed. METHODS: The postoperative courses of 50 eyes of 47 consecutive patients who underwent pars plana vitrectomy and silicone oil injection for the management of complicated retinal detachments were reviewed retrospectively. The outcomes of patients who underwent silicone oil removal and/or glaucoma surgery also were evaluated. RESULTS: The mean overall postoperative IOP before any glaucoma surgery was 16.7 +/- 9.3 mmHg (range, 0 to 45 mmHg), with a mean follow-up of 16.6 +/- 12.1 months (range, 2 to 51 months). Twenty-four (48%) eyes had postoperative IOPs of at least 25 mmHg and IOP elevations of at least 10 mmHg above the preoperative levels. Twenty-one (42%) eyes underwent complete removal of silicone oil and/or glaucoma surgery to effect IOP control. The IOPs were controlled to 21 mmHg or less (but > 5 mmHg) in 8 of 14 eyes that underwent removal of silicone oil alone, in 3 of 5 eyes that underwent Molteno implantation, and in 1 eye that underwent Nd:YAG transscleral cyclophotocoagulation, but not in 1 eye that underwent a modified Schocket procedure (mean follow-up, 13.5 +/- 11.0 months; range, 0.2 to 33 months). CONCLUSION: Intraocular pressure elevation is a common occurrence after intravitreal silicone oil injection. The underlying mechanism may often be multifactorial in nature. Patients in whom uncontrolled IOP develops may benefit from aggressive medical and/or surgical treatment with silicone oil removal, glaucoma implants, or cyclodestructive procedures.     

Results of penetrating keratoplasty for visual rehabilitation after Acanthamoeba keratitis

PURPOSE: To assess the results of penetrating keratoplasty in quiet eyes after resolution of Acanthamoeba keratitis. DESIGN: A retrospective interventional case series. METHODS: Penetrating keratoplasty was undertaken in 13 eyes of 13 patients with an average age of 29 +/- 13 years and a history of Acanthamoeba keratitis that was diagnosed by culture and/or confocal microscopy between January 1995 and September 2004. All eyes were observed for at least 3 months (average, 5 months) after the discontinuation of antiamebic therapy that had been administered for at least 4.5 months. In vivo confocal microscopy was used to ensure that no residual amoeba were present before the operation. Two keratoplasties were combined with a valve insertion; five keratoplasties were combined with cataract extraction, and one keratoplasty was preceded by a ciliary laser ablation. RESULTS: Postoperative best-corrected visual acuity ranged from 20/40 to 20/15, with the exception of one eye with advanced glaucoma that did not improve from a preoperative vision of light perception. No eye experienced rejection or amoebic recurrences, and 12 grafts remained clear throughout the follow-up period (8 months to 9 years; median, 23 months). One graft failed at 4 months because of uncontrolled glaucoma. The eye was regrafted, and the graft remained clear during the 28 months of follow-up evaluation. Two eyes with preoperatively diagnosed glaucoma needed subsequent surgery to control their intraocular pressure. CONCLUSION: Penetrating keratoplasty for visual restoration after Acanthamoeba keratitis appears to have an excellent long-term prognosis, provided amoebic infection has resolved and concurrent glaucoma is controlled.     

穿透性角膜移植术治疗真菌性角膜溃疡穿孔

目的 探讨穿透性角膜移植术治疗真菌性角膜溃疡穿孔的临床疗效。方法 对1994年至2003年在青岛眼科医院行穿透性角膜移植术的40例（40只眼）真菌性角膜溃疡穿孔患者进行随访,随访时间为6～24个月,观察术后视力变化和真菌复发、植片排斥、继发性青光眼、并发性白内障等并发症的发生情况。结果 40例患者中,39例（97．5％）成功地保存了眼球,38例（95．0％）不同程度地提高了视力。穿透性角膜移植术后,4例（10．0％）患者真菌复发,其中3例用药物治愈,1例因合并真菌性眼内炎用药物不能控制而摘除眼球;15例（37．5％）患者植片发生排斥,其中12例经抗排斥治疗植片转为透明,3例因药物治疗无效而行二次穿透性角膜移植术;3例（7．5％）患者植片发生溃疡,其中2例治愈,1例因合并角膜内皮功能失代偿而行二次穿透性角膜移植术;5例（12．5％）患者继发青光眼,眼压均得到成功控制;5例（12．5％）患者发生并发性白内障,其中3例行白内障摘除术。其余患者术后随访期间眼部情况稳定,植片保持透明。最终随访时,36例（90．0％）患者角膜植片透明。结论 穿透性角膜移植术是治疗真菌性角膜溃疡穿孔的有效手术方式,是挽救眼球和视力的主要手段。     

Molteno/von Denffer drainage implants in therapy-refractory glaucomas

BACKGROUND: In glaucoma eyes in which the pressure regulation was not possible with drugs and surgery or which were blind already, we treated the patients with a Molteno implant by von Denffer. MATERIALS AND METHODS: In 10 years (1995 to 2004) we treated 19 eyes with a glaucoma drainage device -- the Molteno implant developed by von Denffer. The average age of the patients was 64 (range: 15 to 77) years. On average 3,1 operations were realised before the implant. The average eye pressure was 44 mm Hg preoperatively. Our patients suffered from different glaucomatous diseases: 7 primary glaucomas (congenital, open and narrow angle glaucoma) and secondary: neovascular glaucoma (4), PEX glaucoma (2), traumatic glaucoma (3) and postoperative glaucoma (3). RESULTS: The intraocular pressure had a successful outcome of under 20 mm Hg in 13 eyes, 5 patients out of these were treated with 1 to 3 drugs. Early complications (flat anterior chamber, hyphaema, hypotonia) were reversible. Late complications were phthisis bulbi (3), explantation of the implant (2) and one evisceration bulbi. We found an improvement of the visual acuity in 4 cases in traumatic and postoperative glaucoma. The stabilisation of visual acuity was possible in primary glaucoma. CONCLUSIONS: The implantation of the Molteno implant by von Denffer is an ultimate ratio in eyes with persistent high intraocular pressure. A durable reduction of the pressure is possible in two-thirds and the conservation of the bulbus was achieved in three-fourths of the patients.     

Molteno implant and refractory glaucoma. Evaluation of postoperative IOP control and complications with a modified surgical procedure

BACKGROUND: Management of refractory glaucoma is difficult because classic medical and surgical treatments are ineffective in controlling highly elevated intraocular pressure (IOP). Drainage implants are an alternative to cyclodestructive procedures in refractory glaucoma. The double-plate Molteno implant, a tube linked to two polypropylene plates, allows aqueous humor drainage from the anterior chamber towards the posterior subconjunctival spaces. The main postoperative complication is severe hypotony, potentially responsible for a decrease in visual acuity in cases of advanced glaucoma. Surgical modifications such as external tube occlusion can reduce postoperative hypotony. However, tube occlusion may lead to transient postoperative hypertony. Our retrospective study reports on double-plate Molteno implantation with intraoperative external tube occlusion associated with trabeculectomy in some cases. MATERIAL AND METHODS: Thirteen eyes of 13 patients with refractory glaucoma were included in the study (5 cases of open angle glaucoma, 7 cases of secondary glaucoma, one case of primary congenital glaucoma). All had ocular hypertony despite maximal tolerable medical treatment; 84.5% had previously undergone trabeculectomy with mitomycin (1-5 procedures) and 61% had undergone cyclophotocoagulation (1-4 sessions). All underwent double-plate Molteno implantation with external tube occlusion between 1993 and 2001. In three cases, intraoperative trabeculectomy was also performed. Visual acuity, IOP, relevant medical treatment and potential complications were reported at each follow-up visit. Complete success was defined as IOP less than 21 mmHg without treatment, while IOP control with medical treatment was considered as relative success. RESULTS: Mean (+/-SD) follow-up was 2.9+/-2.1 years (range, 9 months to 8 years). Mean (+/-SD) initial and final IOPs were 35.2+/-7 mmHg and 17.1+/-5 mmHg, respectively, i.e., a 50% IOP decrease. Mean (+/-SD) initial and final medical treatments were, respectively, 4.3+/-1.5 (61% with systemic acetazolamide) and 1.3+/-1.4 (without acetazolamide). The complete success rate was 38.5% and relative success 92.3%. Immediate postoperative hypertony occurred in 60% of the cases with external tube occlusion alone (10 cases). This hypertony was controlled with medical treatment in 2/3 of the cases but required surgical reintervention in 1/3 of the cases. For patients with intraoperative trabeculectomy (3 cases), postoperative immediate IOP without medical treatment was 2, 5 and 8 mmHg respectively. Complications reported were flat anterior chamber (1 case), visual acuity decrease (4 cases), lens opacification (1 case), macular edema (1 case), corneal edema (2 cases: 1 transient, 1 corneal decompensation) and long-term refractory hypertony (1 case). CONCLUSION: The double-plate Molteno implant is effective in controlling IOP in refractory glaucoma. External tube occlusion prevents complications related to excessive filtration; however, it may lead to transient postoperative hypertony. This hypertony can be avoided when simultaneous trabeculectomy is performed. Corneal decompensation remains the major complication of this surgical procedure.     

Visual outcomes and complications following posterior iris-claw aphakic intraocular lens implantation combined with penetrating keratoplasty

Background

To evaluate the indication, visual outcome, and complication rate after implantation of a posterior iris-claw aphakic intraocular lens (IOL) during penetrating keratoplasty.

Methods

This retrospective study comprised 23 eyes (23 patients) without adequate capsule support undergoing posterior iris-claw aphakic IOL implantation (Verisyse?/Artisan®) during penetrating keratoplasty between 2005 and 2010. Mean follow-up was 18 months (range from 12 to 37 months).

Results

The IOLs were inserted during an IOL exchange in 17 eyes and as a secondary procedure in six aphakic eyes. Pseudophakic bullous keratopathy with corneal scar after anterior chamber intraocular lens (ACIOL) was the main indication for penetrating keratoplasty in 16 eyes (69.6 %). The final corrected distance visual acuity (CDVA) in logMAR (mean 1.0?±?0.46) improved significantly (p?<?0.05) compared to the preoperative CDVA (mean 1.8?±?0.73). Twenty eyes (86.9 %) had a final visual acuity in logMAR better than the pre-operative CDVA. The mean postoperative IOP 16.3 mmHg?±?4.0 was not significantly (p?>?0.05) higher compared to the preoperative IOP 15.6 mmHg?±?5.1. Complications included slight temporary pupil ovalization in three eyes (13.0 %) and iris-claw IOL sublocation in three eyes (13.0 %); all IOLs could be easily repositioned. Cystoid macular edema occured in one eye (4.3 %) 8 weeks after primary surgery. All grafts remained clear without any sign of graft rejection.

Conclusions

Retropupillar iris-claw IOL during penetrating keratoplasty provides good visual outcomes with a favorable complication rate, and can be used for a wide range of indications in eyes without adequate capsule support.     

MANAGEMENT OF UNCONTROLLED GLAUCOMA WITH THE MOLTENO SYSTEM

In glaucomatous eyes refractory to medication, laser techniques and conventional drainage surgery, intraocular pressure is often high, and visual loss rapid. In this situation a reliable, robust artificial outflow system is required. Molteno has evolved a plastic tube and plate device combined with a fibrosis suppression medication regimen. Thirty-eight eyes of 32 patients with uncontrolled glaucoma were treated with the Molteno system. Six months after operation mean intraocular pressure had been reduced from 41.0 ± 13.6 to 16.2 ± 5.6 mmHg. Eighteen eyes had pressures of 20 mmHg or less on no hypotensive therapy, 17 on reduced treatment. Three eyes had a pressure of 21 to 35 mmHg on treatment at six months. The 13 aphakic eyes responded as well as 25 phakic eyes. Five eyes with rubeotic glaucoma demonstrated pressures of less than 20 mmHg without therapy, four eyes with traumatic glaucoma required continuing medication with three having pressures below 22 mmHg. Of the seven eyes with uveitic glaucoma, one was lost, two required maintenance therapy; five of six surviving eyes had pressures below 20 mmHg. Fifteen eyes with congenital or juvenile glaucoma achieved pressures below 20 mmHg, three of these with timolol drops, three with timolol and acetazolamide, and nine with no treatment. While seven of seven eyes with refractory primary open-angle glaucoma attained pressures below 20 mmHg. all seven needed continuing mild hypotensive therapy. Eleven eyes underwent a one-stage procedure, while 27 eyes required a two-stage operation. Twenty-eight eyes received fibrosis suppression medication after the second stage, and 24 maintained or improved their preoperative visual acuity. Results have been encouraging: in general the Molteno system is recommended as the second drainage operation in all glaucomatous eyes in which conventional therapy has failed, and as the primary surgical procedure (after laser techniques) in eyes with rubeotic and uveitic glaucoma. Ciliary body destructive procedures should be restricted to control of symptoms in blind eyes.     

穿透性角膜移植聯合房水引流裝置植入治瘵嚴重角膜病變合并青光眼

目的觀察穿透性角膜移植聯合房水引流裝置植入術治瘵嚴重角膜病變合并難治性青光眼的臨床效果和安全性.方法1996年以來對13衹嚴重角膜病燮合并難治性青光眼的患眼一次施行穿透性角膜移植術和Ahmed青光眼閥植入術.術後随診觀察至少11個月,平均20個月.觀察項目主要是角膜移植片的透明情况、房水引流裝置的硅管有無阻塞、視力、眼壓和并發癥.結果視力提高者10衹眼(76.9%),眼壓降至正常者11衹眼(84.6%),角膜植片透明者9衹眼(69.2%),房水引流管通暢者12衹眼(92.3%).結論穿透性角膜移植術同時聯合房水引流裝置植入術治瘵嚴重角膜病燮合并青光眼可達到滿意的降眼壓效果,改善角膜移植片的透明度,提高患者的視功能.     

Posterior chamber IOL implantation during keratoplasty for aphakic or pseudophakic corneal edema

Because of their many advantages, posterior chamber (PC) intraocular lenses (IOLs) were sutured to the posterior iris (in the absence of a lens capsule) in combination with penetrating keratoplasty for aphakic and pseudophakic corneal edema in 53 cases. Secondary PC IOL implantations were performed in aphakic corneal edema (nine cases), and IOLs were exchanged for PC IOLs in pseudophakic corneal edema (44 cases). Ninety-six percent of the grafts remained clear. Forty-three percent of the eyes had 20/40 or better visual acuity, 38% between 20/50 and 20/200, and 19% worse than 20/200, with an average follow-up time of 6.4 (range 3-13) months. The most common cause of poor vision was cystoid macular edema present preoperatively in 20 eyes and postoperatively in 22 eyes. Other causes of persistent visual impairment included macular degeneration (five cases), retinal detachment (two cases), preoperative glaucoma damage (one case), severe postoperative glaucoma damage (one case), endophthalmitis (one case), and graft rejection (one case). Our short-term results indicate that this procedure may be a viable alternative to the use of secondary anterior chamber IOL implantation during penetrating keratoplasty.     

Cyclodiode photocoagulation for refractory glaucoma after penetrating keratoplasty.

OBJECTIVE: This study analyzes the results of intraocular pressure (IOP) reduction by contact diode cycloablation (cyclodiode) in cases of refractory glaucoma after penetrating keratoplasty. DESIGN: Retrospective noncomparative, interventional case series. PARTICIPANTS: Twenty-eight eyes in 28 patients attending the Moorfields Eye Hospital. INTERVENTION: Cyclodiode (40 applications x 1.5 W x 1.5 seconds over 270-300 degrees ) was used to control the IOP in refractory glaucoma after penetrating keratoplasty. MAIN OUTCOME MEASURES: Postoperative IOP, graft status, visual acuity, and number of antiglaucoma medications were recorded after cyclodiode treatment. RESULTS: Cyclodiode resulted in a reduction of IOP from a median of 33 mmHg (interquartile range [28, 40.5]) to a median of 15 mmHg (interquartile range [12, 20.5]). Most patients had a significant lowering in IOP with a median reduction of 16 mmHg (interquartile range [12, 25]; P < 0.0001). IOPs of 6 to 21 mmHg were achieved in 22 patients (79%). Sixteen patients (57%) required more than one treatment with cyclodiode to control the IOP, with three patients (11%) requiring three treatments and two patients (7%) requiring four treatments. Visual acuity improved (> two Snellen lines of acuity) in three patients (11%) and remained the same (+/- one Snellen line) in 17 patients (61%). The mean number of antiglaucoma medications before cycloablation was 2.6 and was 1.8 after treatment (P < 0.001). Of the 19 patients (68%) with originally clear grafts, three grafts (16%) developed opacification. One patient (4%), with a history of nanophthalmos and recurrent uveal effusion, had delayed hypotony (IOP < 6 mmHg) occurring 46 months after the diode treatment. All patients had at least 6 months follow-up. CONCLUSIONS: These patients have often undergone multiple previous complicated ocular interventions and are often not suitable for filtration surgery. Reduction of IOP with maintenance of visual acuity and a good safety profile was achieved in most patients in this study but may require multiple treatments. We propose cyclodiode as an effective treatment for many patients in the management of refractory glaucoma after penetrating keratoplasty.